Bristol-Myers Gets Europe OK for Sprycel in Form of Leukemia

Date : 02/11/2019 @ 12:47PM
Source : Dow Jones News
Stock : Bristol-Myers Squibb Company (BMY)
Quote : 46.81  -0.49 (-1.04%) @ 10:31PM
Bristol Myers Sqibb share price Chart

Bristol-Myers Gets Europe OK for Sprycel in Form of Leukemia

Bristol Myers Sqibb (NYSE:BMY)
Historical Stock Chart

6 Months : From Nov 2018 to May 2019

Click Here for more Bristol Myers Sqibb Charts.
   By Colin Kellaher 
 

Bristol-Myers Squibb Co. (BMY) on Monday said the European Commission approved the company's Sprycel in combination with chemotherapy for children with a form of leukemia.

The New York biopharmaceutical company said the approval covers the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia and includes both the tablet and powder formulations.

Bristol-Myers said the approval marks the second pediatric leukemia indication for Sprycel in Europe.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

February 11, 2019 07:32 ET (12:32 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest BMY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20190524 22:56:21